Saracatinib (formerly also known as AZD-0530; AZD0530) is a novel, potent Src kinase inhibitor with potential antineoplastic activity. It inhibits Src with an IC50 of 2.7 nM in cell-free assays, and also potently inhibits other kinases such as c-Yes, Fyn, Lyn, Blk, Fgr and Lck; Saracatinib is less active against Abl and EGFR (L858R and […]

UM-164, a dasatinib analogue, is a potent and dual inhibitor of the Src/p38 kinase with potential anticancer activity for Triple-Negative Breast Cancer (TNBC). It is a promising lead compound for developing the first targeted therapeutic strategy against TNBC. c-Src has been shown to play a pivotal role in breast cancer progression, metastasis, and angiogenesis. In […]

Src Inhibitor 1 (Src-I1) is a novel, potent and selective dual site inhibitor of Src tyrosine kinases with potential anticancer activity. It acts by competitively binding to both the ATP- and peptide-binding sites (IC50 = 44 nM for Src and 88nM for Lck, respectively). Src is a non-receptor tyrosine kinase that is deregulated in many […]